Skip to content
DataLookout
Menu

Dana-Farber Cancer Institute clinical trial pipeline

Get alerts when Dana-Farber Cancer Institute's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

18 trials changed in the last 30 days: 0 stopped, 9 with notable changes, 9 with minor changes only.

  1. Minor: Nivolumab or Nivolumab/Ipilimumab · Progessive/ Recurrent Meningioma Study completion pushed from Oct 1, 2026 to Apr 1, 2027 Dana-Farber Cancer InstitutePhase 2 NCT02648997
  2. Minor: Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Study completion pushed from Dec 2026 to Dec 2027 Dana-Farber Cancer InstitutePhase 1 NCT01937468
  3. Minor: ACT · Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) Primary completion date changed from estimate of Sep 24, 2026 to Oct 26, 2026 Dana-Farber Cancer InstituteNot applicable NCT04917796
  4. Minor: RISE in HR NBL · Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma Trial sites expanded: 6 → 9 locations Dana-Farber Cancer InstituteNot applicable NCT06831552
  5. Notable: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL Primary completion moved earlier from Apr 2026 to Jun 2019 Dana-Farber Cancer InstitutePhase 1 NCT02787369
  6. Notable: COMPASSION Study Primary completion pushed from Oct 1, 2026 to Oct 1, 2028 Dana-Farber Cancer InstituteNot applicable NCT06507930
  7. Notable: HYPE · High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study Primary completion pushed from Sep 24, 2026 to Sep 24, 2027 Dana-Farber Cancer InstituteNot applicable NCT05740839
  8. Minor: RECTIFY-1 · Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer Primary completion pushed from Jan 1, 2027 to Jun 1, 2027 Dana-Farber Cancer InstitutePhase 2 NCT07735624
  9. Minor: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Trial completed Dana-Farber Cancer InstitutePhase 1/2 NCT03534323
  10. Notable: Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue Primary completion pushed from Aug 31, 2026 to Aug 31, 2027 Dana-Farber Cancer InstituteNot applicable NCT03657628
  11. Notable: Resistance and Aerobic Exercise for Prevention · Dense Breasts (REP-D) Primary completion pushed from Sep 30, 2026 to Sep 30, 2027 Dana-Farber Cancer InstituteNot applicable NCT06322888
  12. Notable: Dance Study for Post-surgical Pain in Breast Cancer Survivors Primary completion pushed from Feb 28, 2026 to Sep 28, 2027 Dana-Farber Cancer InstituteNot applicable NCT06758102
  13. Notable: SMARCA4/2 Inhibitor for POU2F3-Positive SCLC Recruitment opened Dana-Farber Cancer InstitutePhase 2 NCT07551635
  14. Minor: RESTART · Impact of Exercise on the Complications of Corticosteroids · GVHD: the RESTART Trial Enrollment closed, study ongoing Dana-Farber Cancer InstituteNot applicable NCT05236062
  15. Minor: IPI-145 Plus FCR in Previously Untreated, Younger · CLL Study completion pushed from Jul 2026 to Dec 2026 Dana-Farber Cancer InstitutePhase 1/2 NCT02158091
  16. Minor: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML Study completion pushed from Sep 1, 2026 to Dec 1, 2026 Dana-Farber Cancer InstitutePhase 1 NCT03709758
  17. Notable: I-MAC · Ivonescimab · Advanced, Metastatic Salivary Gland Cancers Primary completion pushed from Jul 1, 2026 to Jul 1, 2027 Dana-Farber Cancer InstitutePhase 2 NCT06805617
  18. Notable: Nivolumab and Ipilimumab in Children and Young · INI1-Negative Cancers Results posted: Oct 20, 2026 Dana-Farber Cancer InstitutePhase 2 NCT04416568
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07938463 Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC Phase 1 Not Yet Recruiting
2026-11-06 NCT07921589 Pilot Testing ACCOMPANI: A Nurse-Targeted Intervention to Promote Psychosocial Equity in… Not Yet Recruiting
2026-10-27 NCT07898813 Daraxonrasib in Resectable PDAC Phase 1 Not Yet Recruiting

Active trials by phase

Early Phase 1
5
Phase 1
35
Phase 1/2
12
Phase 2
70
Phase 3
2
Phase 4
1
Not charted: 109 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 41

Get alerts when Dana-Farber Cancer Institute's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free